Clinical trials: Immunity to Influenza Vaccine
Influenza
Study Evaluating 13 Valent Pneumococcal Conjugate Vaccine With Trivalent Inactivated Influenza Vaccine
This study is to evaluate the safety, tolerability and immune response when 13-valent pneumococcal conjugate vaccine (13vPnC) and the trivalent inactivated flu vaccine (TIV) are given together to healthy adults aged 50-59 years…
- Trial name
- NCT00521586
- Testing
- 13 valent pneumococcal conjugate vaccine
- Where
- 41 sites in United States
- Volunteers
- 1,116 people, healthy volunteers welcome
- Sponsor
- Pfizer
Influenza
Immune Responses in Health Care Personnel
This is an investigator-initiated 10 year long open cohort observational study, aiming to increase the understanding of the humoral and cellular immunological mechanisms of vaccination against influenza, including effects of…
- Trial name
- NCT03323112
- Testing
- influenza vaccine
- Where
- Finland
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Finnish Institute for Health and Welfare
Influenza
B-cell Immunity to Influenza (SLVP017) - Years 2 (2010) & 3 (2011)
In this exploratory study, investigators will be looking at immune response differences between age groups and between the two different influenza vaccines given to identical twins, vaccine-naive young adults and elderly…
- Trial name
- NCT03020498
- Testing
- Fluzone, FluMist
- Volunteers
- 91 people, healthy volunteers welcome
- Sponsor
- Stanford University
Seasonal Influenza Vaccination
Adaptive Immune Response to Seasonal Influenza Vaccination (AIGI)
AIGI (Adaptive Immune Response to Seasonal Influenza Vaccination) is a prospective clinical study aiming at studying the kinetics of vaccine-specific antibody production after seasonal influenza vaccination in health care workers.
- Trial name
- (AIGI) (NCT05129436)
- Testing
- Vaxigrip Tetra 2020/2021
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- University Medicine Greifswald
Influenza
Trial to Evaluate the Immune Response to OPV When Administered Concomitantly With CAIV-T to Healthy Children.
Phase III trial to evaluate the immune response to oral poliovirus vaccine (OPV) when administered concomitantly with CAIV-T to healthy children.
- Trial name
- NCT00192426
- Testing
- CAIV-T
- Volunteers
- 2,400 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Influenza, Human
VRC 307: A Double-Blind, Randomized Phase I Study of the Safety and Immunogenicity of a Prime-Boost Schedule of the Investigational DNA Trivalent Influenza Vaccine, VRC-FLUDNA047-00-VP, Followed by the 2008/2009 Seasonal Influenza Trivalent Inactivat...
Objectives: To evaluate the safety and tolerability of a prime-boost study regimen that includes the recombinant DNA vaccine followed by licensed 2008/2009 FluLaval(Registered Trademark) in adults ages 18-50 years and adults ages…
- Trial name
- NCT00858611
- Testing
- VRC-FLUDNA047-00-VP, Flulaval (Registered) Seasonal Influenza Vaccine
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Immune Response to Influenza Vaccine in HIV-Infected Individuals
This study will evaluate how HIV infection, including CD4 cell count and viral load, affects the patient's ability to produce antibodies in response to vaccination with the influenza (flu) vaccine.
- Trial name
- NCT00069914
- Where
- United States
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza
Demonstrate the Superiority of the Immune Response of Adjuvanted Influenza Vaccine Induced in an Adult Population
The study is designed to demonstrate a meaningful difference in immunogenicity between the candidate adjuvanted vaccine compared to the licensed Fluarix vaccine in subjects aged 50 years and above.
- Trial name
- NCT00377585
- Testing
- Fluarix, adjuvanted influenza vaccine
- Where
- 30 sites in United States, Belgium and 2 more
- Volunteers
- 3,350 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, Virus Diseases
Single Group Study of the Safety of and Immune Response to a Bird Flu Vaccine (H7N3) in Healthy Adults
Over the past decade, avian influenza (AI) has become a major health concern. The development of safe and effective vaccines against avian strains infecting people is important.
- Trial name
- NCT00516035
- Testing
- Live Influenza A Vaccine H7N3 (6-2) AA ca Recombinant (A/chicken/British Columbia/CN-6/2004 x A/Ann Arbor/6/60 ca)
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza
The Dynamics of the Immune Responses to Repeat Influenza Vaccination Exposures (DRIVE III) Study
This study will provide novel insight into the effects of repeat influenza vaccination with Flublok and FluMist on the strength and breadth of immune responses to influenza, the mechanisms underlying heterogeneity in vaccine…
- Trial name
- DRIVE III (NCT07240922)
- Testing
- Live attenuated influenza vaccine, recombinant hemagglutinin influenza vaccine
- Where
- Hong Kong
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- The University of Hong Kong
Influenza
Comparison of Full-dose Flu Vaccine to Half-dose Flu Vaccine
This study compared full-dose Flu vaccine to half-dose Flu-vaccine during the 2004-2005 flu season.
- Trial name
- NCT00283283
- Testing
- Fluzone® (Aventis Pasteur inactivated influenza vaccine)
- Where
- 2 sites in United States
- Volunteers
- 1,316 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
2009 H1N1 Influenza
Effect of Age and Prior Immunity on Response to H1N1 Vaccines in Children
A total of 51 children between the ages of 4 and 9 will be randomized to receive a two dose schedule of either licensed live attenuated A/California/07/09 influenza vaccine (LAIV) or licensed inactivated A/California/07/09…
- Trial name
- H1N1Children (NCT01097941)
- Testing
- Live Attenuated H1N1 Influenza Vaccine, Influenza A (H1N1) 2009 Monovalent Vaccine, Influenza A (H1N1) 2009 Monovalent Vaccine/ Influenza A (H1N1) Monovalent Vaccine Live
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Rochester
Influenza, Virus Diseases
Single Group Study of the Safety of and Immune Response to a Bird Flu Virus Vaccine (H5N1) in Healthy Adults
Over the past decade, avian influenza (AI) has become a major health concern. The development of a safe and effective vaccine against H5N1 infection is important.
- Trial name
- NCT00488046
- Testing
- H5N1 (6-2) AA ca Recombinant (A/Hong Kong/213/2003 x A/AnnArbor/6/60 ca)
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza
Optimizing Influenza Vaccination in Surgical Oncology Patients
Seasonal influenza (flu) is a significant and sometimes serious health issue in the U.S. The Centers for Disease Control (CDC) estimates that over 200,000 people are hospitalized in the U.S each year related to the flu.
- Trial name
- NCT01698177
- Testing
- Influenza vaccine
- Where
- United States
- Volunteers
- 204 people
- Sponsor
- Stony Brook University
Nutritional Anemia in Mothers., Nutritional Anemia in Infants.
Vitamin B12 Supplementation During Pregnancy
Nutritional anemia is a major public health problem among children and women in developing countries. Despite ongoing national program of supplementing pregnant women with iron-folate, prevalence of anemia is 39% among pregnant…
- Trial name
- NCT01795131
- Testing
- Vitamin B12
- Where
- Bangladesh
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- International Centre for Diarrhoeal Disease Research, Bangladesh
Influenza, Influenza Immunisation
Analysis of Bone Marrow and Blood B Cell Immune Responses to Influenza Vaccination
This was a Phase IV open label and single arm study, with the aim of enrolling up to 55 healthy males and non-pregnant females in a single site, age 18-49 years old, inclusive.
- Trial name
- NCT02485639
- Testing
- Influenza Virus Vaccine Inactivated
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Safety Markers of Adjuvanted Influenza Vaccine
Placebo Controlled Study to Generate Data Characterising Clinical Events, Physiological Responses and Immune Responses
The purpose of this protocol is to generate a set of data that will be analysed by integrated systems biology approach, for validation in subsequent clinical trials or in animal models.
- Trial name
- NCT02523287
- Testing
- Fluad, Saline
- Where
- Belgium
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- University Hospital, Ghent
COPD
Responses to Live Attenuated Influenza Virus (LAIV) in Chronic Obstructive Pulmonary Disease (COPD)
This study will determine the functional status of the nasal immune environment with LAIV exposure in COPD persons with frequent exacerbations (defined as individuals with two or more episodes of worsening in COPD symptoms…
- Trial name
- NCT04901455
- Testing
- LAIV
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Influenza (Healthy Volunteers)
Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Taiwanese Adults 65 Years of Age and Older
Primary Objective: Immunogenicity: To describe the immune response induced by high-dose quadrivalent influenza vaccine (QIV-HD) and AdimFlu-S (QIS) by hemagglutinin inhibition (HAI) measurement method in all participants.
- Trial name
- NCT04537234
- Testing
- High-Dose Quadrivalent Influenza Vaccine, Standard-Dose Quadrivalent Influenza Vaccine
- Where
- 4 sites in Taiwan
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza, Virus Diseases
Safety of and Immune Response to a Bird Flu Virus Vaccine (H5N1) in Healthy Adults
Avian influenza (AI), or bird flu, has recently become a major health concern in Asia and other parts of the world. The need for a vaccine to prevent the spread of AI among livestock and to humans is sorely needed.
- Trial name
- NCT00347672
- Testing
- H5N1 (6-2) AA ca Recombinant (A/VietNam/1203/2004 x A/AnnArbor/6/60/ca)
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)